{"id":"W4394689596","doi":"10.1038/s41571-024-00886-y","title":"Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Immune system; Blockade; Vascular endothelial growth factor; Aflibercept; Cancer research; Angiogenesis; Pharmacology; Bevacizumab; Oncology; Immunology; VEGF receptors; Internal medicine; Chemotherapy; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.02281407,0.001121933,0.01239608,0.000196841,0.0001279976,0.0001132563,0.001280723,0.008872905,0.0001970716],"category_scores_gemma":[0.03832521,0.0008093031,0.01142099,0.0004738776,0.0004911602,0.000006927309,0.001056224,0.005102834,0.0009216639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002064199,"about_ca_system_score_gemma":0.003564478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002206533,"about_ca_topic_score_gemma":0.0001094654,"domain_scores_codex":[0.9764127,0.008199383,0.01218429,0.002264607,0.0002951043,0.000643987],"domain_scores_gemma":[0.9852554,0.00710924,0.004772335,0.002006838,0.0002768413,0.0005793593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001204477,0.001495251,0.000001567861,0.001627206,0.001512512,0.0000624704,0.000003868866,4.17703e-8,0.00001377952,0.0003524537,0.157334,0.8374764],"study_design_scores_gemma":[0.004673367,0.001795259,0.000001859065,0.006181819,0.01078089,0.00003909135,0.000004874263,0.000003807544,0.00001075183,0.0003636421,0.9753376,0.0008070781],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002336411,0.9774843,0.0001497086,0.001109716,0.01482332,0.003561051,0.002068174,0.00004453584,0.0007358422],"genre_scores_gemma":[0.0000243304,0.9752054,0.001474624,0.001814288,0.01272957,0.0005624973,0.007296721,0.0001788639,0.0007136712],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8366693,"threshold_uncertainty_score":0.9998562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2805150098880188,"score_gpt":0.5924041186574771,"score_spread":0.3118891087694583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}